Market Overview-
The global duchenne muscular dystrophy treatment market size is expected to gain momentum owing to the increasing awareness regarding the efficacy of the treatment among people during the forecast period. This information is published by Fortune Business Insights™ in an upcoming report, titled, “Duchenne Muscular Dystrophy Treatment Market, 2021-2028.” The number of clinical studies evaluating prospective treatments is increasing. Corticosteroid-based anti-inflammatory therapy is the only accepted pharmaceutical treatment for duchenne muscular dystrophy(DMD). Drug discovery and development in the pharmaceutical industry has developed considerably in recent years. For instance, according to the National Organization of Rare Disorder (NORD), around one in every 3,500 male births suffers from DMD. It is characterised by weakness and wasting (atrophy) of the pelvic muscles, which is followed by involvement of the shoulder muscles.
Request a Sample Copy of the Research Report
COVID-19 Impact-
Economic Impact Due to Covid-19 to Hinder Growth
The market for duchenne muscular dystrophy treatment is a vibrant industry with many prospects for growth, but the present COVID-19 conditions have produced uncertainty in forecasts, revisions in short-term planning goals, and an emphasis on near-term cost management and long-term complexity management.Growth in the market varied greatly in 2020, as firms swiftly aligned their strategies to the existing market conditions.
To get to know more about the short-term and long-term impact of COVID19 on this market, please visit:https://www.fortunebusinessinsights.com/industry-reports/duchenne-muscular-dystrophy-dmd-treatment-market-101863
Segments-
By treatment, the market for duchenne muscular dystrophy treatment is segmented into molecular therapies, steroid therapies, non-steroidal anti-inflammatory drugs, and others. On the basis of distribution channel, the market is segregated into hospital, retail, and online. Finally, by geography, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Quick Buy Duchenne Muscular Dystrophy Treatment Market
What does the Report Include?
The report for duchenne muscular dystrophy treatment offers any detail that is crucial for scaling business in the following years is provided to the market. It goes through all of the important market characteristics and growth tactics that will ensure success for companies operating in the worldwide market.
Drivers & Restraints-
Increasing Demand for Exon Skipping to Stimulate Growth
The increasing demand for exon skipping is expected to boost the global duchenne muscular dystrophy treatment market growth during the forecast period. Exon-skipping therapy is one of the most effective treatments for restoring the expression of a shortened but functional dystrophin protein.One possible therapeutic approach is to mask an exon at the site where the others are missing, allowing the remaining exons to come together. The Food and Medication Administration (FDA) approved Sarepta's exon skipping drug VYONDYS 53 (golodirsen) for the treatment of Duchenne muscular dystrophy in December 2019. These initiatives are likely to favor the adoption of the product worldwide.
REGIONAL INSIGHTS
Increasing Investment in R&D Activities to Promote Growthin North America
North America is expected to hold the largest global duchenne muscular dystrophy treatment market share during the forecast period. This is due to new product breakthroughs, increasing healthcare costs, and proactive government awareness campaigns owing to an increased prevalence of DMD. Moreover, the United States has dominated the regional market and is expected to maintain its lead backed by growing focus on clinical studies.
Europe is anticipated to hold a significant position in the market. The increasing frequency of genetic disorders across the region, as well as better healthcare infrastructure, care standards, research plans, clinical research, and trials, are all contributing to the higher market share. There have been notable medicine approvals in Europe in the last five years, with the first being approved in 2014. Early medication approval, a diverse patient pool, and medical tourism are some of the key factors driving Europe's revenue share.
Have Any Query? Ask Our Experts
Competitive Landscape-
Key Players to Focus on Partnership to Strengthen their Market Position
The number of patients is predicted to decrease as a result of increased campaigns and awareness programmes. Several companies are dedicated to new drug research for uncommon diseases, which is expected to favour the product’s adoption. As a result, many other therapeutic disciplines lack a well-established market. During the predicted period, however, it is expected to grow rapidly and expand.
Industry Development-
- February 2019:CENTOGENE AG and Sarepta Therapeutics launched a year-long strategic agreement with the goal of increasing the number of patients diagnosed with duchenne muscular dystrophy in the Middle East and North Africa.
List of Key Players Profiled in the Global Market for Duchenne Muscular Dystrophy Treatment:
- BioMarin
- Bristol-Myers Squibb Company
- FibroGen Inc.
- NobelPharma Co.
- NIPPON SHINYAKU CO. LTD.
- Pfizer Inc.
- Sarepta Therapeutics
- Elli Lily and Company
About Us:
Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: [email protected]
LinkedIn: https://www.linkedin.com/company/fortune-business-insights
Facebook: https://www.facebook.com/FortuneBusinessInsightsPvtLtd
Twitter: https://twitter.com/FBInsightPvtLtdDuchenne Muscular Dystrophy Treatment Market
However, it is also inherited from parents or caused due to a new mutation.
There are various therapies and drugs to control DMD, however, there is still no cure for duchenne muscular dystrophy.Major driving factors in the global duchenne muscular dystrophy market are the introduction of novel drugs and therapies, disease-modifying therapies, strong support from various companies for drug development and support from patient advocacy groups on the regulatory approval process.
The symptoms include muscle weakness, difficulty in walking and breathing and intellectual disability.
Meanwhile, human clinical trials are also underway to find out effective therapy.Various pharmaceutical companies and organizations are increasingly investing in the research and development activities to come up with an effective treatment for duchenne muscular dystrophy.
Moreover, new therapies aim to repair muscle damage caused due to the absence of dystrophin.
Hospitals pharmacies are expected to be the largest distributors in the duchenne muscular dystrophy market.
Global Duchenne Muscular Dystrophy Market: OverviewDuchenne muscular dystrophy is a medical condition that develops due to shortage of protein called “dystrophin”.
It causes deterioration and break down of muscles, which results in walking difficulty and limited general mobility.
Weakness and wasting (atrophy) of the muscles of the pelvic area characterize duchenne muscular dystrophy and it is followed by the involvement of the shoulder muscles.In a report on the global duchenne muscular dystrophy market by Transparency Market Research offers clear view of the market with every detail that is relevant for scaling business in the coming years.
It extensively covers the necessary market dynamics and growth strategies that are sure to offer success mantra for the companies operating in the global duchenne muscular dystrophy market.Request COVID Analysis on Duchenne Muscular Dystrophy Industry Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=28145 Global Duchenne Muscular Dystrophy Market: Notable DevelopmentsSome important developments that are expected to shape the future strategies of the global duchenne muscular dystrophy market.In July 2019, three clinical trials were conducted on a new drug; an antisense oligonucleotide.
The acquisition is expected to broaden the portfolio of Eli Lilly and Company.This year GlaxoSmithKline plc reached an agreement with Pfizer Inc in a bid to combine their consumer health businesses into a new world-leading joint venture.A few of the prominent market players are BioMarin Pharmaceutical Inc., Catabasis Pharmaceuticals Inc., GlaxoSmithKline Plc., Santhera Pharmaceuticals Holding AG, ReveraGen BioPharma Inc., and Akashi Therapeutics Inc.Request Customization on Duchenne Muscular Dystrophy Industry Market Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=CR_id=28145 Global Duchenne Muscular Dystrophy Market: Key TrendsThe global duchenne muscular dystrophy market is likely to gain traction due to the following factors:Increased Research and Development Activities to Boost MarketThe global duchenne muscular dystrophy market is estimated to gain traction from increased research and development activities, augmented demand for efficacious therapies among patients, and introduction of novel disease therapies.
Furthermore, rising prevalence of the disease is projected to propel the global duchenne muscular dystrophy market towards growth.At present, there is a rise in the number of clinical trials for examining the future course of treatment for duchenne muscular dystrophy.
